Boehringer Ingelheim

New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
CP Wire
Jardiance
Boehringer Ingelheim
Eli Lilly
diabetes
type 2 diabetes
Flag link:
New Analysis Suggests that Jardiance Could Add Years to Life Expectancy of Adults With Type 2 Diabetes and Cardiovascular Disease
Jardiance
Boehringer Ingelheim
Eli Lilly
Flag link:
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Lilly, Boehringer hit heart safety mark with Januvia rival Tradjenta. Is that enough?
Fierce Pharma
Boehringer Ingelheim
Eli Lilly
Tradjenta
diabetes
Flag link:
Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal
Boehringer Ingelheim joins the crowd and goes all-in on oncolytic viruses, buying ViraTherapeutics in $244M deal
Endpoints
Boehringer Ingelheim
ViraTherapeutics
M&A
Flag link:
Cooperation agreement between Boehringer Ingelheim and Tsinghua University (Beijing)
Cooperation agreement between Boehringer Ingelheim and Tsinghua University (Beijing)
GoinPharma
Boehringer Ingelheim
Tsinghua University
Flag link:
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
CP Wire
antibiotics
Boehringer Ingelheim
drug development
Flag link:
Boehringer Ingelheim and Tsinghua University Collaborate to Harness the Immune System to Better Fight Infectious Diseases
Boehringer Ingelheim
Flag link:
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Boehringer, Lilly diabetes drug Tradjenta succeeds in cardiovascular outcome trial
Pharmaceutical Business Review
Boehringer Ingelheim
Eli Lilly
clinical trials
diabetes
Tradjenta
Flag link:
Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Boehringer Ingelheim lands option on cystic fibrosis gene therapy
Fierce Biotech
Boehringer Ingelheim
cystic fibrosis
Oxford BioMedica
gene therapy
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Trajenta Meets Primary Endpoint in Cardiovascular Trial
CP Wire
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Trajenta Meets Primary Endpoint in Cardiovascular Trial
Boehringer Ingelheim
Eli Lilly
Trajenta
Flag link:
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
CP Wire
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
Flag link:
Boehringer Ingelheim Licenses Novel TCRm Antibody for Cancer Treatment
Boehringer Ingelheim
Eureka Therapeutics
monoclonal antibodies
Flag link:
According to new market survey, pharma industry continues to invest heavily on basic research
According to new market survey, pharma industry continues to invest heavily on basic research
GoinPharma
R&D
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
CP Wire
Boehringer Ingelheim
animal health
Europe
Flag link:
Boehringer Ingelheim Invests More Than $230 Million in Veterinary Public Health Production Center in Europe's “Vaccine Valley”
Boehringer Ingelheim
Flag link:
Boehringer Ingelheim BioXcellence adds fill-finish line to China plant
Boehringer Ingelheim BioXcellence adds fill-finish line to China plant
Fierce Pharma
Boehringer Ingelheim
China
drug manufacturing
biologics
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
CP Wire
CHMP
Boehringer Ingelheim
Eli Lilly
EMA
Jardiance
Synjardy
Glyxambi
diabetes
Flag link:
CHMP Issues Positive Opinion to Expand Labeling of Jardiance, Synjardy and Glyxambi to Include Positive Effects on Cardiovascular and Renal Outcomes
Boehringer Ingelheim
Eli Lilly
Jardiance
Synjardy
Glyxambi
Flag link:
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
ADA: Lilly, BI's Jardiance cut kidney disease progression in Empa-Reg analysis
Fierce Pharma
ADA
kidney disease
Eli Lilly
Boehringer Ingelheim
Flag link:

Pages